DHR at $172.81 shows mixed signals: 4/4 beats, 9/9 Piotroski, 124% FCF/NI conversion, RECOVERY setup with asymmetry 4.11 and 28% upside — but bear_case flags geographic concentration (59% non-US), weak growth (3.4 revenue), confirmed downtrend below 200-day MA — action_note 'Mixed signals. Hold existing position.'
Thesis pillars
| Pillar | Expectation | Engine signal |
|---|---|---|
Quality 6.8 with notes 'Excellent cash conversion: 124% FCF/NI' and 'Strong Piotroski F-Score: 9/9' plus operating_margin 9.2/10 — DHR converts earnings to cash at a top-decile rate. Quality breakdown | FCF/NI conversion stays above 110% and Piotroski F-Score stays 8+/9 over the next 2 refreshes. | →stable |
| CounterFCF/NI 124% can mean working-capital release rather than structural cash generation; if working-capital normalizes, FCF/NI reverts toward 90-100%. | ||
Bull_case 'Strong earnings beat streak (4/4)' with catalyst notes 'Perfect beat streak: 4Q', avg_surprise_pct 6.93%, and consistent 6-10% beats across all four quarters — execution against estimates is durable. Bull case (item 1) | Beat count holds at 4/4 with avg_surprise_pct above 5% by the 2026-07-21 print. | →stable |
| CounterDiagnostics & Research demand normalization post-COVID continues; beats may be against guided-down estimates rather than genuine upside. | ||
Bear_case 'Concentration risk — Geographic: outside the U.S. (59.0%)' with risk.notes confirming '1 HIGH (10-K Item 1A)' — 59% non-US revenue is exposed to FX, China demand, and trade policy shocks. Bear case (item 1) | Risk subscore stays above 6.0 and no new HIGH concentration risk adds to bear_case in next 2 refreshes. | →stable |
| CounterGlobal diversification across instruments customers is a feature, not a bug — concentration framing penalizes geographic breadth that smooths cyclical demand. | ||
Quality 6.8 with notes 'Excellent cash conversion: 124% FCF/NI' and 'Strong Piotroski F-Score: 9/9' plus operating_margin 9.2/10 — DHR converts earnings to cash at a top-decile rate.
→stable- Expectation
- FCF/NI conversion stays above 110% and Piotroski F-Score stays 8+/9 over the next 2 refreshes.
CounterFCF/NI 124% can mean working-capital release rather than structural cash generation; if working-capital normalizes, FCF/NI reverts toward 90-100%.
Bull_case 'Strong earnings beat streak (4/4)' with catalyst notes 'Perfect beat streak: 4Q', avg_surprise_pct 6.93%, and consistent 6-10% beats across all four quarters — execution against estimates is durable.
→stable- Expectation
- Beat count holds at 4/4 with avg_surprise_pct above 5% by the 2026-07-21 print.
CounterDiagnostics & Research demand normalization post-COVID continues; beats may be against guided-down estimates rather than genuine upside.
Bear_case 'Concentration risk — Geographic: outside the U.S. (59.0%)' with risk.notes confirming '1 HIGH (10-K Item 1A)' — 59% non-US revenue is exposed to FX, China demand, and trade policy shocks.
→stable- Expectation
- Risk subscore stays above 6.0 and no new HIGH concentration risk adds to bear_case in next 2 refreshes.
CounterGlobal diversification across instruments customers is a feature, not a bug — concentration framing penalizes geographic breadth that smooths cyclical demand.
▸ Show 2 more pillars (SSR-indexed, visually truncated)▾ Show fewer
Bear_case 'Below 200-MA, MA slope -1.5%/30d (confirmed downtrend)' contradicts the recovery setup — even though MACD/OBV are improving, ma_position component is 4.0/10 and 52w_position 4.3/10.
→stable- Expectation
- Price reclaims 200-day MA and ma_position component rises above 6.0 within 2 refreshes.
CounterMACD bullish + rising OBV + RSI 47 are the early-recovery template; downtrend confirmation lags MACD by ~30 days, so the 'confirmed downtrend' tag may invert before the next refresh.
Bull_case 'Analyst upside: 28%' with sentiment 7.9 (analyst_rating 9.0, price_target 9.3) and TP $221.67 versus $172.81 spot — sell-side is well above price.
→stable- Expectation
- Analyst take_profit holds above $215 with sentiment subscore above 7.5 over next 2 refreshes.
CounterSell-side targets routinely lag rather than lead in healthcare; 28% upside with a confirmed downtrend rarely closes within the implied 12-month horizon.
Danaher Corporation (DHR) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $182.67, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology... Read more
Hold if already holding. Not a fresh buy at $182.67, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth. Chart setup: Death cross but MACD improving, RSI 68. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.6/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.80, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-05-30Recent Developments — Danaher Corporation
Latest news
- Danaher (DHR) Receives Buy Rating from Citi with $230 Price Targ - GuruFocus — GuruFocus positive
- Danaher (DHR) Downgraded by Citigroup -- Price Target Lowered to $95 - GuruFocus — GuruFocus negative
- Danaher Corporation Shs Cert Deposito Arg Repr 0.018518518 Sh Balance Sheet – BCBA:DHR.CI - TradingView — TradingView neutral
- Jefferies Financial Group Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price - MarketBeat — MarketBeat negative
- Sivik Global Healthcare LLC Trims Stock Holdings in Danaher Corporation $DHR - MarketBeat — MarketBeat neutral
Generated 2026-05-30T00:22:22Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $182.67, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth. Chart setup: Death cross but MACD improving, RSI 68. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $220.85 (+20.9%), stop $172.23 (−6.1%), A.R:R 1.8:1. Score 5.6/10, moderate confidence.
Take-profit target: $220.85 (+20.9% upside). Target $220.85 (+20.9%), stop $172.23 (−6.1%), A.R:R 1.8:1. Stop-loss: $172.23.
Concentration risk — Geographic: outside the U.S. (59.0%); Weak growth; Below 200-MA, MA slope -1.6%/30d (confirmed downtrend).
Danaher Corporation trades at a P/E of 34.9 (forward 19.9). TrendMatrix value score: 5.7/10. Verdict: Hold.
30 analysts cover DHR with a consensus score of 4.2/5. Average price target: $245.
What does Danaher Corporation do?Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and...
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.